Blueprint, Alexion start rare disease collaboration

Blueprint Medicines (Cambridge, Mass.) and Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) started a research collaboration to develop small molecules against an undisclosed activated kinase that causes a rare genetic disease.

Alexion will be responsible for clinical development and commercialization of candidates. Blueprint will identify candidates using its platform and will conduct all pre-IND research (see BioCentury, Nov. 10, 2014). ...